ABSTRACT
INTRODUCTION
The protein RAP1 was originally identified as a silencer-binding factor at HMR (1) and was recently shown to mediate DNA-loop formation in vitro at HML (2) . RAP1 was also proposed to function as both a repressor and activator protein (3) . Two independently identified proteins, TUF, which binds to the RPGbox in genes coding for components of the translation apparatus (4) , and GRF1 (5), have similar properties to RAP1 (6) and may be identical factors (3, 6, 7) . Potential and proven RAPl-binding sites have now been identified in numerous genes encoding unrelated products (3, 6, (8) (9) (10) (11) (12) (13) . The protein RAP1 therefore appears to possess multiple activities: it appears to bind to many unrelated promoters, it can activate or repress expression and it can bind differentially to the same promoter to affect regulation. The promoter-specific properties of RAP1 could be conferred either by differences in binding affinity due to the nature or the context of the binding sites, or to the influence of flanking DNA, or to interactions with adjacent proteins that may themselves be regulated or to modifications to the RAP1 protein. There is already evidence that binding affinity is influenced by the recognition site and by flanking sequences (3, 6) . The question of modifications to the RAP1 protein has not been addressed.
In the yeast Saccharomyces cerevisiae the phosphoglycerate kinase (PGK) gene encodes one of the highly expressed glycolytic enzymes accounting for 1 -5% of total mRNA and protein (14) . The PGK gene, like most glycolytic genes, is subject to carbonsource regulation. RNA levels are low on non-fermentable carbon sources such as pyruvate and high on glucose (8, 14) . The promoter region of PGK contains an upstream activating sequence (PGK UAS , 15) that comprises at least three different sequence elements (16) . These are 1) an activator core (16) , 2) three repeats of the motif 5'CTTCC3' (16) and 3) a strong protein-binding site called Ypp (17) . The activator core, located between bases -458 and -473, contains a RAPl-binding site. Deletion of the activator core reduces PGK expression to less than 20% (16) . We have recently proven that the RAPl-binding site in the activator core is bound by RAP1 present in crude nuclear protein extracts and by RAP1 produced in vitro (8) . The CTTCC blocks are necessary for maximal expression but not essential for transcriptional activation (16) . Each CTTCC block contributes differendy to PGK expression and the cognate binding factors, if any, have not been identified (16) . The Ypp, located between bases -4% to -523, binds the ARS-binding factor ABF1 (5, 18, 19) . The role of Ypp is at present unclear, as its deletion does not affect the activity of the authentic PGK promoter (8) . It does, however, augment the function of the RAPl-binding site in an artificial assay promoter (17) .
We have recently shown that the binding of RAP1 to the activator core sequence of PGK is carbon-source dependent. Little
• To whom correspondence should be addressed or no DNA-protein complex was observed when nuclear protein extracts from pyruvate-grown cells were used in gel retardation assays (8) . On the other hand, the expression of RAP1 is not regulated. Similar amounts of RAP 1-specific RNA (8) and RAPl-/3-galactosidase fusion protein (unpublished data) were detected in cells grown on glucose or on pyruvate. The carbonsource-dependent binding of RAP1 to PGK UAS may therefore be explained by post-translational modification such as phosphorylation.
Phosphorylation is a common post-translational modification that affects the properties of a wide range of proteins with different functions. The binding of at least two transcription factors, the c-fos serum response factor (20) and the nuclear factor CREB (21) , is influenced by phosphorylation. In addition several viral proteins that bind DNA are phosphoproteins (22) (23) (24) . In this paper we have addressed the role of phosphorylation of RAP 1 in determining binding to the PGK promoter.
MATERIALS AND METHODS

Strains and growth conditions
The Escherichia coli strain used was MC1061 (F~ araD139, (ara, leu)1696, lacY74, gal U~, gal K~, hsr~, hsm + , str A). The yeast strain used was Saccharomyces cerevisiae DBY745 (a adel-100 leu2-3 Ieu2-112 ura3-52). E. coli cultures were grown at 37°C in L-broth (1% tryptone, 0.5% yeast extract, 0.5% NaCl). Yeast cultures were grown at 30°C in YEPD (1 % yeast extract, 2% peptone, 2% glucose) or minimal medium containing 0.67% yeast nitrogen base without amino acid (Difco) supplemented with the necessary amino acids and 2% glucose.
DNA probes
The UAS of PGK is schematically represented in Figure 1 . The DNA fragments used in this study and their corresponding locations in the UAS are also depicted. The DNA fragments Z + (-409 to -473) was subcloned from PGK into pSP46 (16, 25) . DNA fragments Z +6 (-406 to -479), Z +23 (-406 to -4%) and Z +45 (-406 to -518) were isolated from plasmids pMA731, pMA732 and pKV530, respectively, by BamHUEcoOl09l digests (15) . The isolated fragments were endlabelled using cr^P dTTP (400Ci/mmol) or a 32 P dCTP (3000Ci/mmol) and Klenow polymerase (Amersham).
Retardation Gel analysis
Preparation of yeast nuclear protein extracts by homogenization and production of in vitro translated RAP1 using a rabbit reticulocyte lysate system (Promega) were as described previously (8, 25) . The gel retardation assay was based on the methods of Fried and Crothers and Gamer and Revzin (26, 27) . Binding reactions using yeast nuclear protein extracts contained 1/tg of nuclear protein. This was incubated with the labelled DNA fragment in a buffer containing 5% glycerol, lmM Na 2 EDTA, lOmM /3-mercaptoethanol, 25mM Tris-HCl pH 7.5, 25mM NaCl and 20mM KC1. 200ng of calf-thymus DNA was added to each binding reaction as a non-specific competitor. After a thirtyminute incubation at 22°C, DNA-protein complexes were resolved by electrophoresis on a 5% polyacrylamide gel containing 0.5xTBE. Binding reactions using the in vitro translated RAP1 were similar to those using the yeast protein extracts. 0.2-0.5/tl of RAP1 or mock lysate was incubated with the labelled probe in the presence of 400ng of calf-thymus DNA. DNA-protein complexes were resolved as described earlier.
Phosphatase treatment
Calf intestine alkaline phosphatase and potato acid phosphatase were obtained from Boehringer Corporation London (products 713023 and 108197, respectively). Insoluble alkaline phosphatase was obtained from Sigma (P-0762). These enzymes were added to binding reactions without the labelled DNA fragment. The enzyme was allowed to react with the extract or in vitro translated RAP1 for fifteen minutes at 22°C before the labelled probe and the non-specific competitor DNA were added.
RESULTS
Phosphatase treatment of a crude nuclear protein extract abolishes RAP1 binding to the PGK Z + fragment
The PGK UAS , located between bases -402 to -538 upstream of the initiation codon, has been subcloned into smaller fragments (16, 25) . The Z + fragment contains sequences from -409 to -473. This region contains the RAPl-binding site and the three 5'CTTCC3' blocks. The Z + fragment has been shown to produce a single major complex when retarded with a crude yeast nuclear protein extract prepared from glucose-grown cells (16) . This complex was caused by the binding of RAP1 to the consensus binding site located between -458 and -473 and its occurrence was carbon-source dependent (8) . To examine the role of phosphorylation on RAP1 binding activity we treated the crude yeast nuclear protein extract with calf intestine alkaline phosphatase ( To further support the notion that dephosphorylation modifies RAP1 binding to the Z + fragment the experiment was repeated using another source of phosphatase. Potato acid phosphatase was used and the results ( Fig. 2 lanes 9-13) confirmed the observations obtained using alkaline phosphatase, namely that the RAP 1-DNA complex (R) was replaced by a faster-migrating complex (C). This faster-migrating complex was not a modified form of RAPl as it was not recognised by a specific anti-RAPl antibody. We used a concentration of acid phosphatase that allowed both the normal RAP1-Z + complex (R) and the fastermigrating complex (C) to form (Fig. 3 lanes 3 and 6) . The addition of specific anti-RAPl antibody (a generous gift from D. Shore, Columbia University) would abolish any complex formation related to RAPl binding (Fig. 3 , compare lanes <t and 5; 8). The use of anti-RAPl antibody abolished the formation of the normal slow-migrating complex R but had no effect on the formation of the faster-migrating complex C (Fig. 3, compare  lanes 6 and 7) . In order to eliminate the presence of other yeast proteins which might interact with the Z + fragment specifically or non-specifically after phosphatase treatment and complicate the result, in vitro translated (TVT) RAPl protein was used (8) . Figure 4A shows that there was no binding of the mock lysate proteins (an IVT reaction without any RNA), with or without phosphatase treatment, to the Z + fragment (Fig. 4A lanes 3 and  4) . Moreover, the binding of the IVT RAPl to the Z + fragment was abolished after phosphatase treatment (Fig. 4A , compare lanes 5 and 6). This abolition of RAPl binding was not due to protein degradation as incubation of IVT RAPl with phosphatase does not cause degradation (data not shown). This confirmed our results using the crude extracts, which showed that dephosphorylation of RAPl abolished its binding to the Z + fragment. These changes could be inhibited by the addition of the phosphatase inhibitor 30mM ammonium molybdate (Fig. 4B,  compare lanes 3 to 4) . Furthermore, the DNA-binding activity of dephosphorylated RAPl can be restored by phosphorylating the protein. Insoluble phosphatase was used to dephosphorylate IVT RAPl and the phosphatase was removed by centrifugation through a column of glass beads. Half of this phosphatase-treated lysate was then treated with catalytic unit of cAMP-dependent protein kinase (ca. 40 picomole unit, Sigma P-2645). Both lysates :alff intestine alkaline phosphatase potato acid phosphata so were then used for retardation gel assays. Figure 4C shows that insoluble phosphatase decreased the DNA binding activity of RAPl while protein kinase restored its binding to the Z + fragment (Fig. 4C, compare lanes 3 and 4) . DNA sequences 5' to the activator core sequence determine the modifiction of RAPl binding The Z + fragment, which contains sequences -409 to -473 upstream of the initiation codon of PGK, is a subfragment of the PGK UAS located between bases -402 to -538. The PGK UAS , denoted as the X fragment, has been shown to give more than one protein-DNA complex when retarded with a crude nuclear protein extract (25) . When the X fragment was used to test the effect of phosphatase on RAPl binding a contrasting result to that for the Z + fragment was obtained. Figure 5A shows that when IVT RAPl was pretreated with alkaline phosphatase an increase in binding to the X fragment was detected (Fig. 5A , compare lanes 5 and 6). This result was very surprising because the two DNA fragments, Z + and X, contain the same RAPl core recognition sequence. This prompted us to investigate whether the nature of the DNA fragment affects RAPl binding.
In the X fragment the RAPl-binding site is located roughly in the centre, flanked by 65bp from one end and 61bp from the other end, of the DNA fragment. In the Z + fragment the RAP1-binding site is located on one end adjacent to the polylinker cloning site where the fragment was isolated. In order to place the RAPl binding site in the central region of the DNA fragment plasmid pSP46-Z + (16) was digested with SalUBanl and a 208bp fragment (Z +B ) was isolated and used for retardation gel analysis. This fragment, Z +B , contains additional pSP46 vector DNA sequence upstream of the Z + fragment. In this fragment the RAPl-binding site is flanked by 138bp and 60bp, thus imitating the X fragment. The result indicated that the binding of in vitro produced RAPl to this fragment was also decreased by phosphatase treatment (Fig. 5B, compare lanes 5 and 6) . This implied that the position of the RAPl-binding site in the fragments 4) and one of which (lane 4) was then treated with catalytic unit of cAMP-dependent protein kinase (ca. 40pMU) prior to retardation gel analysis. Lane 7 is a control to show that the protein kinase does not contain DNA-binding activity.
being tested cannot account for the differences in the effects of phosphatase treatment on RAP1 binding to the Z + fragment and to the X fragment.
A previous study using the methylation interference footprinting technique indicated that RAP1 interacted with sequences upstream of the activator core sequence of the Z + fragment (8) . This suggested that RAP1 might contact sequences upstream of -473, the end point of the Z + fragment. Furthermore, a close comparison between the RAP 1-binding consensus and the activator core sequence of DNA fragments Z + and Z +B revealed that these fragments do not contain matches to the first two bases of the consensus. DNA fragments containing various lengths of PGK sequences upstream of the 5' end point of the Z + fragment were therefore tested. DNA fragments Z +6 , Z
+23
and Z +45 , containing 6, 23 and 45 additional authentic bases, respectively, upstream of the 5' end point of the Z + fragment, were isolated from plasmids pMA731, pMA732 and pKV530, respectively (15) . Retardation gel analysis showed that the binding of RAP1 to these fragments was increased by phosphatase treatment (Fig. 5C, compare lanes 2 and 3, 5 and 6 , and 8 and 1-3) , Z +23 (lanes 4-6), and Z +45 (lanes 7-9). Lanes 3, 6 and 9 were pretreated with 1 unit of alkaline phosphatase.
9). This suggested that DNA sequences 5' to the activator core sequence of PGK UAS determine the outcome of the phosphorylation-dependent binding of RAPI.
The response of a RAPI DNA binding domain (28) to phosphatase treatment is similar to that of full-length RAPI. Figure 6 shows that the RAPI DNA-binding domain decreased its binding to the Z + and Z +B fragments but increased its binding to the X, Z +6 , Z +23 and the Z +45 fragments, when treated with phosphatase. This implied that the observed responses of RAPI to phosphatase were most likely achieved via the DNAbinding domain.
DISCUSSION
Phosphorylation has been shown to affect the DNA-binding ability and biological activity of numerous cellular components such as c-fos serum response factor (20) , the heat shock element binding protein (29) and cAMP response element binding protein (21) . Here we show that the DNA-binding ability of the yeast RAPI protein is also affected by its phosphorylation state.
Treatment of crude yeast protein extracts and reticulocyte lysates with phosphatase could result in a non-specific interference with RAPI binding. This is however unlikely, as both an increase or decrease of binding with the same extracts have been observed dependent upon the target DNA fragment. The modification of RAPI binding is most likely phosphatase-specific. First, similar results on DNA binding modification were obtained by using calf intestine alkaline phosphatase or potato acid phosphatase (Fig.  2) , suggesting that the effect was not due to the storage buffers of the enzymes. The use of insoluble phosphatase (Fig. 4C) removes the doubt of any buffer effect as no other buffer was supplemented. Second, the modification was inhibited by phosphatase inhibitor, in this case, ammonium molybdate, further indicating that the effect was due to phosphatase (Fig. 4B) . Third, the loss of DNA-binding activity on the Z + fragment caused by phosphatase can be reversed by phosphorylating the protein (Fig.  4C) .
A previous study showed that mutations at the 5' end of the RAP1 recognition site did not affect RAP1 binding (30) . This agrees with our observations that DNA fragments Z + and Z +B bind RAP1 efficiently. However, we show that the mere addition of six authentic base pairs to the Z + fragment, which is fully capable of binding to RAP1, altered its response to RAP1 binding with respect to phosphatase treatment. DNA fragments Z + and derivative Z +B both decreased their binding (Figs. 4A and 5B) while DNA fragments X, Z +6 , Z+ 23 and Z +45 all showed increases in binding when RAP1 was treated with phosphatase ( Figs. 5A and 5C ). This probably reflects the involvement of the 5' end of the RAP 1-recognition site in determining the stability of RAP1 binding, especially in response to phosphatase treatment. DNA sequences 5' to the RAPl-binding site have been shown to be the DNA-bending site induced by RAP1 (30) . It may be possible that phosphorylation affects DNA binding and bending abilities of RAP1 depending on the nature of the sequences 5' to the core recognition site. The involvement of additional sequences may help the protein to recognise different binding sites and to act selectively in response to different stimuli.
It should be noted that the decrease in binding to the Z + fragment in this in vitro assay may not necessarily reflect the in vivo situation. The Z + fragment has been shown to display activation and regulation functions when inserted upstream of an artifical assay promoter (8, 17) . It is likely that the vector sequences adjacent to the RAPl-binding site of the Z + and the Z +B fragments disrupt or de-stabilise the structural integrity of the binding complex during the analysis in vitro (31) while in in vivo situation RAP1 interacts with other promoter elements (32, 33) , thus stabilising its binding to the binding site.
Regulation of transcription involves DNA-protein interactions as well as protein-protein interactions. Using a minimal promoter assay system derived from PGK, we have demonstrated that RAP1 requires additional interactions to form an active transcription complex (17) . Either the Y-binding protein ABF1 which binds -496 to -523 or the CTTCC blocks which probably bind a protein factor, can supply the necessary additional interactions. When we treated a nuclear protein extract with phosphatase we detected a faster-migrating complex (Fig. 2 complex C) in retardation gel analysis. This faster-migrating complex is unlikely to be a modified form of RAP1 because an incubation with specific anti-RAPl antibody prior to DNA binding did not inhibit the formation of this complex (Fig. 3) . Furthermore, this phosphatase-induced complex was also detected when a DNA fragment Z, containing sequences -402 to -460 (25) , which lacks the RAPl-binding site, was used for analysis (unpublished data). This newly detected complex may be a specific DNA-protein complex caused by the interaction of other specific factors with the sequence shared by the Z + and the Z fragments, namely the CTTCC blocks or the yATF (34) binding site located between bases -416 and -425, or it may be a nonspecific complex induced by phosphatase. Further investigation is required to prove that this complex is caused by a specific DNA binding protein.
We have recently identified a minimal functional DNA-binding domain of the protein RAP1 to residues 361 to 596 (28) . An in vitro produced protein containing this minimal DNA-binding domain possesses DNA-binding ability similar to that of fulllength RAP1 (28) . When this protein was treated with phosphatase and retarded with various PGK subfragments a similar result to that of full-length RAPl was observed (Fig. 6) . This implied that the phosphorylation-dependent binding of RAPl is most likely achieved via the binding domain. Located in this minimal-binding domain is a cluster of potential phosphorylation sites for protein kinase C ( Fig. 7; 28) . Moreover, 18 out of a total of 28 potential phosphorylation sites, as determined by a computer search using the PIP program developed by Staden using the kinase recognition sequences described by Leader and Katan (35) , were located in this domain. However, we have no direct evidence, yet, to show that RAPl is a phosphoprotein. The actual phosphorylation site(s) and enzyme(s) involved in modifying RAPl DNA-binding activity, are still waiting for identification.
